Results from first of the “BEAR” clinical study series suggests promise for this disruptive technology
neoSurgical® begins postmarket surveillance study of neoClose® versus standard of care for closing port site incisions in Lap and Robotic surgeries
An emerging medical device manufacturing company (that we’d never come across until now), Advanced Cooling Therapy (ACT), has received CE marking for its first product, the Esophageal Cooling Device (ECD) to control patient temperature. The product is now available to medical professionals in Europe.
According to global market intelligence company Millennium Research Group, the European market for clot management devices will see moderate growth through 2022. Although a number of segments are mature, fast-growing segments such as endovascular treatments for acute ischemic stroke and venous thromboembolism underpin the growth forecast.
Hemasorb Plus is provided ready-to-use and achieves hemostasis by mechanical tamponade. Its proprietary formulation is comprised of granular hydroxyapatite/beta-tricalcium phosphate and water soluble components that are fully synthetic and absorbable.
CorMedix Inc. has gained CE Mark approval for Neutrolin®, a catheter lock solution for patients with central venous catheters on hemodialysis secondary to advanced chronic kidney disease.
Device company Teleflex Inc. is to acquire Israeli company Eon Surgical, Ltd. in a deal, the terms of which have … continue reading “Teleflex Hopes Eon Surgical Acquisition Will Help It Accelerate Microlaparoscopy Adoption”
Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, announced today that two patients diagnosed with severe mitral regurgitation have been treated successfully with the Transfemoral Cardioband™ Annuloplasty System
Difficult decision that it is, the chance to give someone else life after you or your loved one has died can be a source of great and enduring comfort. Two new initiatives driven by UK’s NICE have helped see the number of donations rise dramatically, yet three people a day still die waiting.
Endoscopic device company Apollo Endosurgery, Inc., has announced that its OverStitch™ Endoscopic Suturing System has gained European CE Mark approval. The company plans to immediately launch the system to select centers in several European countries.
London’s Barts Hospital has enrolled its first patients in the ROX Medical CONTROL-HTN international randomized controlled hypertension trial. The study is evaluating the ROX FLOW procedure, which creates a small connection between artery and vein in the upper leg for the treatment of resistant hypertension.
If you’re of a certain vintage, if your bones are osteoporotic and you suffer a hip fracture, you are at risk of suffering one on the other side. In a piece of potentially smart-thinking a Bordeaux company has a minimally invasive device that might protect you against that eventuality.
Israeli company Premia Spine has developed an implant which it says offers patients with certain spinal disorders an alternative to traditional fusion surgeries. The company says it enables a quicker recovery and greatly reduces the risk of reoperation.
Mitral valve repair specialist company NeoChord, has received CE-marking for its technology that allows the implantation of artificial chordae tendinae, a proven technique for the repair of mitral valve prolapse, via a transapical, off-pump procedure.
Early stage orthopedic device company, Soft Tissue Regeneration, has developed a breakthrough tissue engineering platform used to regenerate ligaments and tendons. The company has announced that it has received FDA clearance to market its STR GRAFT, a biodegradable scaffold used for soft tissue augmentation and rotator cuff repair.
Covidien is trumpeting the five-year results of its ClosureFast™ Long-Term European Multi-Centre Study in patients with Chronic Venous Insufficiency. 92% of patients still had effective occlusion of target vessels after five years, supporting the claim that the treatment is durable in the longer term.